Gainers & Losers Of Sep.27: ADXS, BGNE, CDXS, VSAR, ITCI...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of September 27, 2017.

GAINERS

1. Advaxis Inc. (ADXS)

Gained 14.83% to close Wednesday's (Sep.27) trading at $4.49.

News: No news

Near-term catalysts:

-- Completion of the MAA submission for conditional approval of Axalimogene filolisbac in recurrent metastatic, cervical cancer in Europe is expected in the fourth quarter of this year. -- Filing of IND for combination trial with ADXS-DUAL and Bristol Myers' Opdivo for the treatment of women with persistent, recurrent or metastatic cervical cancer is expected in the remainder of this year, with initiation of the trial planned for the first half of 2018. -- Initiation of phase I trial of ADXS-NEO in multiple tumor types is expected in 1H 2018.

2. BeiGene Ltd. (BGNE)

Gained 14.32% to close Wednesday's trading at $100.04.

News: No news

Pipeline:

The Company's most advanced drug candidate is BGB-3111. A head-to-head phase III trial designed to determine whether the quality of response with BGB-3111 in patients with Waldenström's macroglobulinemia is superior to that of Abbvie's Imbruvica is underway. The other oncology clinical drug candidates are BGB-A317, BGB-283 and BGB-290.

3. Marinus Pharmaceuticals Inc. (MRNS)

Gained 10.96% to close Wednesday's trading at $5.87.

Near-term catalysts:

-- Initiate a phase II study of Ganaxolone capsules in women with moderate Postpartum Depression, dubbed Amaryllis, later this year. -- Initiate a phase II study of Ganaxolone IV in patients with status epilepticus later this year.

4. Codexis Inc. (CDXS)

Gained 10.92% to close Wednesday's trading at $6.60.

News: No news

Recent event:

On August 9, 2017, the Company updated its financial guidance for 2017, as follows:

Affirmed total revenues of $50 million to $53 million, which assumes revenue from an anticipated major new deal that the company expects to announce in the near future. Total revenues for 2016 were $48.8 million.

New product sales guidance of between $25 million and $27 million reflects an increase of 63% to 76% over 2016. New product sales in 2016 were $15.3 million.

5. Spectrum Pharmaceuticals Inc. (SPPI)

Gained 10.81% to close Wednesday's trading at $10.97.

News: No news

Near-term catalysts:

-- Top-line data from registrational phase III study of ROLONTIS in the management of chemotherapy-induced neutropenia, dubbed ADVANCE, are expected in Q1, 2018. -- A second smaller study of ROLONTIS, dubbed RECOVER, is enrolling patients in EU and U.S. Enrollment completion is expected in Q1 2018. -- An investigator sponsored phase II trial of Poziotinib in non-small cell lung cancer patients with exon 20 insertion mutations in EGFR or HER2 is underway, and interim results are expected before this year end.

6. Aralez Pharmaceuticals Inc. (ARLZ)

Gained 10.70% to close Wednesday's trading at $2.07.

News: No news

Recent event:

On August 9, 2017, the Company reported financial results for the second quarter and first half of 2017.

Net loss in the second quarter of 2017 widened to $27.5 million or $0.42 per share from $17.5 million or $0.27 per share in the year-ago quarter. Total revenues for the recent second quarter were $27.6 million compared to $12.6 million in the year-ago period.

At June 30, 2017, the Company had cash and cash equivalents of approximately $55.8 million.

LOSERS

1. Intra-Cellular Therapies Inc. (ITCI)

Lost 13.36% to close Wednesday's trading at $16.66.

News: The Company has priced its previously announced underwritten public offering of 9.67 million shares of its common stock at a public offering price of $15.50 per share.

Net proceeds to Intra-Cellular from the offering are expected to be approximately $140.6 million. The offering is expected to close on October 2, 2017, subject to customary closing conditions. The underwriters have a 30-day option to purchase up to an additional 1.45 million shares.

2. Versartis Inc. (VSAR)

Lost 9.82% to close Wednesday's trading at $2.52.

News: No news

Recent event:

Last Thursday (Sep.21, 2017) after the bell, the Company announced that its phase III study of Somavaratan in pre-pubertal children with Growth Hormone Deficiency, dubbed VELOCITY, did not meet the trial goals. The news sent the stock tumbling nearly 88% on Sep.22, 2017.

3. Syros Pharmaceuticals Inc. (SYRS)

Lost 7.59% to close Wednesday's trading at $13.52.

News: No news

Pipeline:

The Company's lead drug candidates are SY-1425, in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers.

Near-term catalysts:

-- Initial clinical data from phase II clinical trial of SY-1425 are expected to be reported in the fourth quarter of 2017. -- Preliminary clinical data from phase I clinical trial of SY-1365 are expected in 2018.